SELLAS Life Sciences (SLS) Total Non-Current Liabilities (2010 - 2022)

SELLAS Life Sciences (SLS) has 13 years of Total Non-Current Liabilities data on file, last reported at $16.1 million in Q4 2022.

• Total Non-Current Liabilities for Q4 2022 came in at $16.1 million, up 185.72% year-over-year; the trailing twelve-month figure through Dec 2022 was $16.1 million (up 185.72% YoY), and the FY2022 annual result was $16.1 million, up 185.72% from the prior year.
• Total Non-Current Liabilities grew to $16.1 million in Q4 2022 per SLS's latest filing, from $13.2 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $30.1 million in Q1 2018 and troughed at $3.9 million in Q1 2020.
• A 5-year average of $10.9 million and a median of $7.2 million in 2019 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2019 and 2022: Total Non-Current Liabilities slumped 79.9% in 2019, then jumped 185.72% in 2022.
• A 5-year view of Total Non-Current Liabilities shows it stood at $7.3 million in 2018, then slipped by 23.69% to $5.6 million in 2019, then soared by 140.1% to $13.5 million in 2020, then plunged by 58.14% to $5.6 million in 2021, then soared by 185.72% to $16.1 million in 2022.
• Business Quant data shows SLS's Total Non-Current Liabilities at $16.1 million in Q4 2022, $13.2 million in Q3 2022, and $13.0 million in Q2 2022.